Key Record Dates
| ClinicalTrials.gov Identifier: | NCT02655224 |
|---|---|
| Brief Title: | A Placebo-Controlled, Phase 3 Study of Relugolix (TAK-385) 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids |
| First Submitted : | January 12, 2016 |
| First Submitted that Met QC Criteria : | January 12, 2016 |
| First Posted : | January 13, 2016 (Estimate) |
| Results First Submitted : | May 16, 2018 |
| Results First Submitted that Met QC Criteria : | December 25, 2018 |
| Results First Posted : | March 22, 2019 |
| Last Update Submitted that Met QC Criteria : | December 25, 2018 |
| Last Update Posted : | March 22, 2019 |